Mass Spectrometry-Based Non-targeted Metabolic Profiling for Disease Detection: Recent Developments.
Mass Spectrometry-Based Non-targeted Metabolic Profiling for Disease Detection: Recent Developments.
复制标题
DOI：
10.1016/j.trac.2019.05.030
复制
发表时间：
2019-09
期刊：
影响因子：
--
通讯作者：
Xiaoling Zang;M. Monge;F. Fernández
中科院分区：
文献类型：
--
作者：
Xiaoling Zang;M. Monge;F. Fernández
质谱（MS）在寻找用于疾病检测的生物标志物方面起着重要作用。准确分析患者的代谢紊乱需要高质量的定量数据。本文介绍了MS非靶向代谢组学研究的最新进展，并将其应用于几种主要的常见人类疾病的检测，重点介绍了研究队列、MS平台、统计分析和鉴别代谢物鉴定。总结了通过代谢组学发现的2型糖尿病、心血管疾病、肝细胞癌、乳腺癌和前列腺癌的潜在疾病生物标志物，并讨论了其局限性。
Mass spectrometry (MS) plays an important role in seeking biomarkers for disease detection. High-quality quantitative data is needed for accurate analysis of metabolic perturbations in patients. This article describes recent developments in MS-based non-targeted metabolomics research with applications to the detection of several major common human diseases, focusing on study cohorts, MS platforms utilized, statistical analyses and discriminant metabolite identification. Potential disease biomarkers recently discovered for type 2 diabetes, cardiovascular disease, hepatocellular carcinoma, breast cancer and prostate cancer through metabolomics are summarized, and limitations are discussed.